{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:20:42Z","timestamp":1787822442720,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"DOI":"10.7759\/cureus.115278","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:46:38Z","timestamp":1787820398000},"source":"Crossref","is-referenced-by-count":0,"title":["Allelic Frequency of Single-Nucleotide Polymorphisms in CYP2C9, VKORC1, and CYP4F2 Genetic Variants in Patients With Mechanical Heart Valves on Acenocoumarol Drug Therapy"],"prefix":"10.7759","author":[{"given":"Ahmad","family":"Najmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Watti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakrishnan","family":"Sadasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Atal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kotnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchula","family":"Santenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyaprakash","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adila","family":"Zehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umra","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84655","article-title":"Long-term outcomes of valve replacement with mechanical prosthesis in patients with valvular heart disease: a single-center retrospective study","volume":"17","author":"Saksena D","year":"2025","unstructured":"Saksena D, Choudhary A, Varma S, Shetty S, Jain V. Long-term outcomes of valve replacement with mechanical prosthesis in patients with valvular heart disease: a single-center retrospective study. Cureus. 2025, 17:e84655. 10.7759\/cureus.84655","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12055-019-00812-3","article-title":"Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery","volume":"35","author":"Choudhary SK","year":"2019","unstructured":"Choudhary SK, Mathew AB, Parhar A, Hote MP, Talwar S, Rajashekhar P. Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery. Indian J Thorac Cardiovasc Surg. 2019, 35:539-47. 10.1007\/s12055-019-00812-3","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom JW","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al.. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013, 369:1206-14. 10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik A","year":"2017","unstructured":"Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017, 43:365-79. 10.1007\/s11239-016-1446-0","journal-title":"J Thromb Thrombolysis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0341","article-title":"Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity","volume":"106","author":"Bodin L","year":"2005","unstructured":"Bodin L, Verstuyft C, Tregouet DA, et al.. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005, 106:135-40. 10.1182\/blood-2005-01-0341","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson JA","year":"2017","unstructured":"Johnson JA, Caudle KE, Gong L, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017, 102:397-404. 10.1002\/cpt.668","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111180","article-title":"Pharmacogenetics to avoid adverse reactions in cardiology: ready for implementation?","volume":"11","author":"Garc\u00eda-Gonz\u00e1lez X","year":"2021","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Salvador-Mart\u00edn S. Pharmacogenetics to avoid adverse reactions in cardiology: ready for implementation?. J Pers Med. 2021, 11:1180. 10.3390\/jpm11111180","journal-title":"J Pers Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500417","article-title":"Pharmacogenetics of warfarin: current status and future challenges","volume":"7","author":"Wadelius M","year":"2007","unstructured":"Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007, 7:99-111. 10.1038\/sj.tpj.6500417","journal-title":"Pharmacogenomics J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-44463","article-title":"Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors","volume":"3","author":"Hylek EM","year":"2003","unstructured":"Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2003, 3:271-8. 10.1055\/s-2003-44463","journal-title":"Semin Vasc Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.02.006","article-title":"Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients","volume":"131","author":"Krishna Kumar D","year":"2013","unstructured":"Krishna Kumar D, Madhan S, Balachander J, Sai Chandran BV, Thamijarassy B, Adithan C. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res. 2013, 131:363-7. 10.1016\/j.thromres.2013.02.006","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051425","article-title":"Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: insights from the nationwide PLECTRUM study","volume":"26","author":"Menichelli D","year":"2021","unstructured":"Menichelli D, Poli D, Antonucci E, et al.. Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: insights from the nationwide PLECTRUM study. Molecules. 2021, 26:1425. 10.3390\/molecules26051425","journal-title":"Molecules"},{"key":"ref12","article-title":"Acenocoumarol: a review of anticoagulant efficacy and safety","volume":"64","author":"Trailokya A","year":"2016","unstructured":"Trailokya A, Hiremath JS, Sawhney J, Mishra YK, Kanhere V, Srinivasa R, Tiwaskar M. Acenocoumarol: a review of anticoagulant efficacy and safety. J Assoc Physicians India. 2016, 64:88-93.","journal-title":"J Assoc Physicians India"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s1734-1140(13)70977-0","article-title":"Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians","volume":"65","author":"Nahar R","year":"2013","unstructured":"Nahar R, Deb R, Saxena R, Puri RD, Verma IC. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians. Pharmacol Rep. 2013, 65:187-94. 10.1016\/s1734-1140(13)70977-0","journal-title":"Pharmacol Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037844","article-title":"Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians","volume":"7","author":"Rathore SS","year":"2012","unstructured":"Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One. 2012, 7:e37844. 10.1371\/journal.pone.0037844","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1791-x","article-title":"An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population","volume":"71","author":"Krishna Kumar D","year":"2015","unstructured":"Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Sai Chandran BV, Balachander J, Adithan C. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Eur J Clin Pharmacol. 2015, 71:173-81. 10.1007\/s00228-014-1791-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2011.4","article-title":"Optimization of warfarin dose by population-specific pharmacogenomic algorithm","volume":"12","author":"Pavani A","year":"2012","unstructured":"Pavani A, Naushad SM, Rupasree Y, et al.. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J. 2012, 12:306-11. 10.1038\/tpj.2011.4","journal-title":"Pharmacogenomics J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.08.643","article-title":"Genetic warfarin dosing: tables versus algorithms","volume":"57","author":"Finkelman BS","year":"2011","unstructured":"Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol. 2011, 57:612-8. 10.1016\/j.jacc.2010.08.643","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed M","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, et al.. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004, 329:15. 10.1136\/bmj.329.7456.15","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.2686","article-title":"Anticoagulation for mechanical aortic valve replacement: an international survey","volume":"41","author":"Gupta S","year":"2020","unstructured":"Gupta S, Belley-Cote E, McEwen C, et al.. Anticoagulation for mechanical aortic valve replacement: an international survey. Eur Heart J. 2020, 41:ehaa946.2686. 10.1093\/ehjci\/ehaa946.2686","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2022.3.2722","article-title":"Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study","volume":"20","author":"Elnour AA","year":"2022","unstructured":"Elnour AA, Ahmed IM, Khalid AK, Elmustafa M. Validation and comparison between two warfarin dosing clinical algorithms and warfarin fixed dosing in specialized heart center: cross-sectional study. Pharm Pract (Granada). 2022, 20:2722. 10.18549\/PharmPract.2022.3.2722","journal-title":"Pharm Pract (Granada)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01014","article-title":"Pharmacogenetic-guided algorithm to improve daily dose of warfarin in elder Han-Chinese population","volume":"11","author":"Ren Y","year":"2020","unstructured":"Ren Y, Yang C, Chen H, Dai D, Wang Y, Zhu H, Wang F. Pharmacogenetic-guided algorithm to improve daily dose of warfarin in elder Han-Chinese population. Front Pharmacol. 2020, 11:1014. 10.3389\/fphar.2020.01014","journal-title":"Front Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9678-3","article-title":"Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients","volume":"34","author":"Bazan NS","year":"2012","unstructured":"Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm. 2012, 34:837-44. 10.1007\/s11096-012-9678-3","journal-title":"Int J Clin Pharm"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S66776","article-title":"Effect of age and sex on warfarin dosing","volume":"6","author":"Khoury G","year":"2014","unstructured":"Khoury G, Sheikh-Taha M. Effect of age and sex on warfarin dosing. Clin Pharmacol. 2014, 6:103-6. 10.2147\/CPAA.S66776","journal-title":"Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144511","article-title":"Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials","volume":"10","author":"Shi C","year":"2015","unstructured":"Shi C, Yan W, Wang G, Wang F, Li Q, Lin N. Pharmacogenetics-based versus conventional dosing of warfarin: a meta-analysis of randomized controlled trials. PLoS One. 2015, 10:e0144511. 10.1371\/journal.pone.0144511","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1235331","article-title":"Application of a warfarin dosing calculator to guide individualized dosing versus empirical adjustment after fixed dosing: a pilot study","volume":"14","author":"Cai X","year":"2023","unstructured":"Cai X, Chen J, Chen M, Xia X, Fang G, Zhang J. Application of a warfarin dosing calculator to guide individualized dosing versus empirical adjustment after fixed dosing: a pilot study. Front Pharmacol. 2023, 14:1235331. 10.3389\/fphar.2023.1235331","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr116","article-title":"Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data","volume":"32","author":"van Schie RM","year":"2011","unstructured":"van Schie RM, Wessels JA, le Cessie S, et al.. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J. 2011, 32:1909-17. 10.1093\/eurheartj\/ehr116","journal-title":"Eur Heart J"},{"key":"ref27","article-title":"Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response","volume":"60","author":"Shalia KK","year":"2012","unstructured":"Shalia KK, Doshi SM, Parikh S, et al.. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. J Assoc Physicians India. 2012, 60:34-8.","journal-title":"J Assoc Physicians India"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.13","article-title":"Integration of genetic, clinical, and INR data to refine warfarin dosing","volume":"87","author":"Lenzini P","year":"2010","unstructured":"Lenzini P, Wadelius M, Kimmel S, et al.. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010, 87:572-8. 10.1038\/clpt.2010.13","journal-title":"Clin Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3109\/03014460.2014.922615","article-title":"Unity in diversity: an overview of the genomic anthropology of India","volume":"41","author":"Mastana SS","year":"2014","unstructured":"Mastana SS. Unity in diversity: an overview of the genomic anthropology of India. Ann Hum Biol. 2014, 41:287-99. 10.3109\/03014460.2014.922615","journal-title":"Ann Hum Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032546","article-title":"Genetic affinities of the central Indian tribal populations","volume":"7","author":"Sharma G","year":"2012","unstructured":"Sharma G, Tamang R, Chaudhary R, et al.. Genetic affinities of the central Indian tribal populations. PLoS One. 2012, 7:e32546. 10.1371\/journal.pone.0032546","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/523728-allelic-frequency-of-single-nucleotide-polymorphisms-in-cyp2c9-vkorc1-and-cyp4f2-genetic-variants-in-patients-with-mechanical-heart-valves-on-acenocoumarol-drug-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:46:39Z","timestamp":1787820399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/523728-allelic-frequency-of-single-nucleotide-polymorphisms-in-cyp2c9-vkorc1-and-cyp4f2-genetic-variants-in-patients-with-mechanical-heart-valves-on-acenocoumarol-drug-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.115278","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}